SCHEMBL5732970

SCHEMBL5732970

COP(=O)(CC(=O)c1cccc(CC2CCOCC2)c1)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PDE4D Q08499 6/20 0.38
▸ PDE4A P27815 4/20 0.38
▸ PDE4B Q07343 4/20 0.38
▸ PDE4C Q08493 4/20 0.38
▸ CCR2 P41597 1/20 0.37
▸ BRD4 O60885 2/20 0.36
▸ CCL2 P13500 1/20 0.36
▸ SLC2A1 P11166 1/20 0.36
▸ MRGPRX4 Q96LA9 1/20 0.36
▸ OPRM1 P35372 2/20 0.36
▸ CCR3 P51677 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ OPRD1 P41143 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732978 0.83 SMN1; SMN2 (0.37) PDE4DPDE4APDE4BPDE4CCCR2
SCHEMBL5734221 0.77 LMNA (0.47) LMNAPOLBMRGPRX4SMN1; SMN2
SCHEMBL23684547 0.77 GRIK1 (0.51) LMNAMRGPRX4OPRM1MEN1KMT2A
SCHEMBL5733021 0.75 CYP4F2 (0.46) LMNAPOLBMRGPRX4SMN1; SMN2
SCHEMBL5734534 0.75 LMNA (0.53) LMNAPOLBMRGPRX4KMT2ASMN1; SMN2
SCHEMBL23684186 0.75 SLC7A5 (0.51) LMNABRD4CCL2MRGPRX4OPRM1
SCHEMBL30260217 0.75 SLC7A5 (0.51) LMNABRD4CCL2MRGPRX4OPRM1
SCHEMBL6476639 0.74 POLB (0.42) LMNAPOLB
SCHEMBL5732625 0.72 LMNA (0.38) LMNAPOLBPDE4DPDE4APDE4B
SCHEMBL5732711 0.71 POLB (0.50) LMNAPOLBMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 — — EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 — — US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 — — EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 — — US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 LMNA 3569/4885POLB 3426/4885PDE4D 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback